Fast Facts: Biosimilars in Hematology and Oncology

Biologics have revolutionized - and are revolutionizing - the treatment of many serious disorders. The evidence acquired from more than 10 years of clinical experience, with more than 50 biosimilar drugs and more than 700 million patient-days' exposure in Europe, shows that approved biosimilars can be used as safely and effectively as originator biologics. Yet concerns persist about biosimilars - particularly in curative cancer treatment, where they are relatively recent therapeutic options. 'Fast Facts: Biosimilars in Hematology and Oncology' provides a concise overview of emerging global practice in this fast-moving area together with practical information on adding biosimilars to a formulary and switching patients. Contents: . Biologics and the need for biosimilars . Why do we need biosimilars? . How is the quality of biosimilar medicines assured? . Legal issues . Switching, interchangeability and extrapolation . Safety and pharmacovigilant . Global issues . Formulary considerations: pharmacy issues . Formulary considerations: supportive care biosimilars . Formulary considerations: therapeutic anti-cancer biosimilars . Communication and awareness